Drug Research

 
Stock Quotes for Drug Research top ^
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for 524689 investment picks
  • Industry: Drug Manufacturers - Major
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for ankurdrugs investment picks

 
News Articles for Drug Research top ^
Celgene Corporation (NASDAQ: CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
Sign-up for Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis investment picks
http://media.marketwire.com/attachments/201011/15201_horizonpharma.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1149179&ProfileId=051205&sourceType=1 DUBLIN, IRELAND --
Sign-up for Horizon Pharma plc Receives Orphan-Drug Designation for ACTIMMUNE(R) (Interferon gamma-1b) in Friedreich's Ataxia investment picks
By Erin McCarthy Repros Therapeutics Inc. said it was notified by the U.S. Food and Drug Administration that there isn't enough clinical information to hold a planned pre-investigational new drug application meeting in November.
Sign-up for Repros Therapeutics shares drop on drug application setback investment picks
By Erin McCarthy Sarepta Therapeutics Inc. said the U.S. Food and Drug Administration is requiring additional data for the new drug application for its Duchenne muscular dystrophy treatment eteplirsen.
Sign-up for Sarepta Therapeutics sees setback in Eteplirsen drug application investment picks
Geron Corp.'s stock (GERN) soared 35% in premarket trade Monday, after the company said the Food and Drug Administration lifted its hold on the investigational new drug application for its cancer treatment imetelstat.
Sign-up for Geron's stock soars after FDA lifts hold on new drug application investment picks
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts will be presented at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, California, December 6-9, 2014, highlighting the following: “Antibody-drug conjugates represent an innovative and important therapeutic approach to targeting cancer.
Sign-up for Seattle Genetics to Present Clinical Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for daclatasvir, an NS5A complex inhibitor, in combination with other agents for the treatment of hepatitis C (HCV). The initial daclatasvir NDA submitted to the FDA focused on its use in combination with asunaprevir, an NS3/4A protease inhibitor.
Sign-up for Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C investment picks
2014/12/2
By William Horobin PARIS--France's Sanofi SA (SAN.FR) said Tuesday the Food and Drug Administration has approved tuberculosis drug Priftin.
Sign-up for Sanofi Gets FDA Approval for TB Drug Priftin investment picks
e-Therapeutics plc (AIM:ETX), the drug discovery and development company, today announces its half year results for the six months ended 31 July 2014.
Sign-up for Four Clinical Trials in Progress; New Drug Candidates in Laboratory Testing investment picks
Esperion Therapeutics Inc. (ESPR) shares rallied in the extended session Wednesday after the drug developer said a mid-stage clinical trial showed its drug candidate significantly lowered bad cholesterol.
Sign-up for Esperion shares rally on cholesterol drug study results investment picks
http://media.marketwire.com/attachments/201305/60668_insys.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1147673&ProfileId=051205&sourceType=1 PHOENIX, AZ --
Sign-up for Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Glioma investment picks
Follows CytRx's Strategy to Develop a Global Oncology Franchise in Numerous Orphan Indications LOS ANGELES , Sept.
Sign-up for CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch)--The validity of some generic drug trials may come into question after a company's apparent software glitch turned up in equipment used for the tests, but U.S. regulators indicate it's unlikely any medicines sold domestically could come into question.
Sign-up for Drug test doubts shouldn't affect U.S., feds say investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Drug Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Drug Related Products Stocks  |  Next: Drug Sales